11 unknown. 11 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Unknown 11 |
| Phase 2 | 6 | Unknown 6 |
Follow Acute Lymphocytic Leukemia: new trials by email Literature Review of Acute Lymphocytic Leukemia trials Research Report on Acute Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia CD19-targeted Chimeric Antigen Receptor (CAR) T Cells - Acute Lymphocytic Leukemia | Phase 1 | Unknown | Shanghai Ming Ju Biotechnology Co., Ltd. | 33 | 2022-04-28 | 2023-02-14 |
| Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 27 | 2021-04-10 | 2021-04-08 |
| CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia CD7 CAR-T cells infusion - T-lymphoblastic Lymphoma, NK/T Cell Lymphoma | Phase 1 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2019-08-25 | 2020-09-28 |
| Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia Autologous CD19-targeting CAR T cells - Acute Lymphocytic Leukemia | Phase 1 | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 20 | 2019-01-02 | 2021-01-20 |
| A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies Drugs and anti-CD19 CAR transduced T cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Second Affiliated Hospital of Guangzhou Medical University | 100 | 2017-06-30 | 2017-06-20 |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-10-01 | 2016-10-25 |
| PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma anti-CD19 CAR-NK cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-09-01 | 2016-12-06 |
| Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-07-01 | 2016-08-01 |
| Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies Fludarabine, Cyclophosphamide, Anti-CD19-CAR transduced T cells - Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia | Phase 1 | Unknown | Shenzhen Second People's Hospital | 36 | 2015-04-01 | 2016-08-03 |
| PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia PR104 - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Proacta, Incorporated | 50 | 2010-01-01 | 2012-08-31 |
| Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia Liposomal Annamycin - Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Callisto Pharmaceuticals | 34 | 2005-10-01 | 2007-12-21 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Leukemia, Prolymphocytic, B-Cell (3) · Lymphoma, Follicular (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Mantle-Cell (3) · Lymphoma (2) · Leukemia, Myeloid, Acute (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Non-Hodgkin (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Hematologic Diseases (11) · Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Leukemia (11) · Leukemia, Lymphoid (11) · Lymphatic Diseases (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Disease Attributes (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Chronic Disease (6) · Leukemia, B-Cell (6)
Antigens, CD19 (3) · Cyclophosphamide (3) · Sensitivity and Specificity (3) · fludarabine (3) · Immunotherapy, Adoptive (2) · Automobiles (1) · Pharmaceutical Preparations (1)
PersonGen BioTherapeutics (Suzhou) Co., Ltd. (4) · Callisto Pharmaceuticals (1) · Hebei Senlang Biotechnology Inc., Ltd. (1) · Proacta, Incorporated (1) · Second Affiliated Hospital of Guangzhou Medical University (1) · Shanghai Ming Ju Biotechnology Co., Ltd. (1) · Shenzhen Second People's Hospital (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (9) · United States (2)
Gary Jacob, PhD (1) · Lin Yang, Ph.D. (1) · Mingjun Wang, MD (1) · Peihua Lu, PhD&MD (1) · Xiaofan Zhu, PhD (1) · Xin Liu, Ph.D. (1) · Xingbing Wang, Ph.D. (1) · Ying Feng, MD (1) · Yu Hu (1)
PMID 25682597, PMID 28054442, PMID 33869653, PMID 34515338, PMID 35126471, PMID 35435984